AVI BioPharma’s therapeutic development programs include lead candidates for Duchenne muscular dystrophy, hemorrhagic virus infections and influenza.
This page was last updated on February 27, 2012.
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |
| DMD - Exon 51 AVI-4658 |
|
||||
| DMD - Exon 50 AVI-5038 |
|
||||
| DMD - Exon 45 |
|
||||
| Ebola VIrus AVI-6002 |
|
||||
| Marburg Virus AVI-6003 |
|
||||
| Influenza Therapy AVI-7100 |
|
||||
| Dengue Virus AVI-6006 |
|
||||
